ReviewSpringerPlus2016
Prognostic role of microRNA-203 in various carcinomas: evidence from a meta-analysis involving 13 studies.
Review in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis.BMJ open · 2018Pooled it
- A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma.SAGE open medicine · 2025Review
- Noncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications.Molecular therapy. Nucleic acids · 2021Review
- The miR-203a Regulatory Network Affects the Proliferation of Chronic Myeloid Leukemia K562 Cells.Frontiers in cell and developmental biology · 2021Article
- Biomarker exploration of microRNA-203 as a promising substrate for predicting poor survival outcome in colorectal cancer.BMC cancer · 2020Article
- Article
- miR-203 affects esophageal cancer cell proliferation, apoptosis and invasion by targeting MAP3K1.Oncology letters · 2020Article
- circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis.Cell death & disease · 2019Article
- MicroRNA expression in pediatric intracranial ependymomas and their potential value for tumor grading.Oncology letters · 2019Article
- MicroRNAs in regulation of triple-negative breast cancer progression.Journal of cancer research and clinical oncology · 2018Review
- Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.International journal of oncology · 2018Article
- Circulating exosomal microRNA-203 is associated with metastasis possibly via inducing tumor-associated macrophages in colorectal cancer.Oncotarget · 2017Article
- MicroRNAs as Biomarkers in Colorectal Cancer.Cancers · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence from recent studies has revealed that microRNA-203 (miR-203) might be an attractive prognostic biomarker for cancer. But controversy still remains. The aim of this meta-analysis was to summarize available evidences and clarify the preliminary predictive value of miR-203 for prognosis in cancer patients. Eligible studies were identified through multiple research strategies in PubMed, EMBASE and Web of Science up to October 2015. Key statistics such as pooled hazard ratios (HR) with 95 % confidence intervals (CIs) were utilized to calculate patient survival. 13 eligible studies with 1600 patients were ultimately enrolled in this meta-analysis. Our results failed to show a significant relation between upregulated miR-203 expression and a favorable overall survival (OS) (HR 1.00, 95 % CI 0.65-1.36) in a random effect model. However, in subgroup analysis, we found that high expression of miR-203 was significantly associated with poor OS in Caucasian patients (HR 1.31, 95 % CI 1.06-1.55). In contrast, for Asian patients, over-expression of miR-203 was an independent prognostic factor for better and OS (HR 0.59, 95 % CI 0.22-0.96). It also suggested that cancer types and miRNA assay method were significant associated with prognosis. The over-expression of miR-203 was effectively predictive of worse prognosis in breast cancer (HR 6.35, 95 % CI 1.34-11.36), pancreatic cancer (HR 1.19, 95 % CI 1.08-1.30), ependymoma (HR 1.35, 95 % CI 1.10-1.61), but for glioma patients, elevated miR-203 is a potential biomarker for predicting better progression of cancer (HR 0.26, 95 % CI -0.02 to 0.54). Besides, for direct miRNA profiling studies, over-expression of miR-203 was an independent prognostic factor for worse OS (HR 6.35, 95 % CI 1.34-11.36). This meta-analysis indicated that ethnicity, tumor type and miRNA assay method mainly contributed to heterogeneity. Considering the insufficient evidence, further relevant studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.